Loading...
Back
C MM
C
AC IMMUNE SA
(ACIU)
2025 6-K
Follow
Summary
Share
Summary
Management Changes
15 May '26
CEO Retirement Announced
12 May '26
Financial Update
30 Apr '26
Trial Progress Announcement
30 Apr '26
Collaboration Amended
7 Apr '26
Financial Filing Summary
13 Mar '26
Clinical Trial Start
24 Feb '26
Trial Enrollment Update
17 Feb '26
Positive Data Release
11 Dec '25
Filing Update
4 Nov '25
Strategic Workforce Reduction
4 Sep '25
AC Immune Filing
5 Aug '25
AGM Results Summary
20 Jun '25
Management Change
11 Jun '25
Management Changes
19 May '25
Filing Overview
30 Apr '25
6-K Filing Summary
13 Mar '25
Management Changes
18 Dec '24
Safety Data Update
10 Dec '24
Positive Clinical Data
14 Nov '24
6-K Filing Update
5 Nov '24
New CMO Appointment
19 Sep '24
Milestone Payment Received
17 Sep '24
FDA Fast Track Granted
28 Aug '24
Open Market Sales
6 Aug '24
Filing Report Summary
6 Aug '24
New Drug Announcement
31 Jul '24
Fast Track Approval
25 Jul '24
Annual Meeting Results
20 Jun '24
Shareholders Meeting
21 May '24
Filing Insights
13 May '24
License Agreement
13 May '24
Form 6-K Filing
14 Mar '24
Agreement Termination
22 Jan '24
Filing Update
3 Jan '24
External Links:
SEC
AC Immune SA filed a 6-K report on November 4, 2025, detailing its interim financial results for the three and nine months ending September 30, 2025.
AI Assistant
Close
AC IMMUNE SA
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.